CONCERT PHARMACEUTICALS, INC. Quarterly Debt-to-equity in % from Q3 2014 to Q3 2022

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Concert Pharmaceuticals, Inc. quarterly Debt-to-equity history and growth rate from Q3 2014 to Q3 2022.
  • Concert Pharmaceuticals, Inc. Debt-to-equity for the quarter ending September 30, 2022 was 42.8 %, a 83.1% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q3 2022 42.8 +19.4 +83.1% Sep 30, 2022
Q2 2022 44.2 +22.9 +108% Jun 30, 2022
Q1 2022 39.2 +18.4 +88.8% Mar 31, 2022
Q4 2021 29.9 +9.43 +46% Dec 31, 2021
Q3 2021 23.4 +0.22 +0.95% Sep 30, 2021
Q2 2021 21.3 -3.65 -14.6% Jun 30, 2021
Q1 2021 20.8 -5.65 -21.4% Mar 31, 2021
Q4 2020 20.5 -6.33 -23.6% Dec 31, 2020
Q3 2020 23.1 +1.4 +6.44% Sep 30, 2020
Q2 2020 24.9 +7.01 +39.1% Jun 30, 2020
Q1 2020 26.4 +12 +83.2% Mar 31, 2020
Q4 2019 26.8 +15.7 +141% Dec 31, 2019
Q3 2019 21.7 +12.2 +128% Sep 30, 2019
Q2 2019 17.9 +9.3 +108% Jun 30, 2019
Q1 2019 14.4 +0.45 +3.22% Mar 31, 2019
Q4 2018 11.1 -5.78 -34.2% Dec 31, 2018
Q3 2018 9.53 -11.7 -55.1% Sep 30, 2018
Q2 2018 8.61 -19.2 -69% Jun 30, 2018
Q1 2018 14 -2.97 -17.5% Mar 31, 2018
Q4 2017 16.9 +1.52 +9.88% Dec 31, 2017
Q3 2017 21.3 +7.06 +49.8% Sep 30, 2017
Q2 2017 27.8 +14.3 +106% Jun 30, 2017
Q1 2017 16.9 +3.47 +25.8% Mar 31, 2017
Q4 2016 15.4 -0.78 -4.83% Dec 31, 2016
Q3 2016 14.2 -8.18 -36.6% Sep 30, 2016
Q2 2016 13.5 -17.6 -56.6% Jun 30, 2016
Q1 2016 13.5 -29.7 -68.8% Mar 31, 2016
Q4 2015 16.2 -34 -67.8% Dec 31, 2015
Q3 2015 22.4 -124 -84.7% Sep 30, 2015
Q2 2015 31 Jun 30, 2015
Q1 2015 43.1 Mar 31, 2015
Q4 2014 50.2 Dec 31, 2014
Q3 2014 146 Sep 30, 2014
* An asterisk sign (*) next to the value indicates that the value is likely invalid.